Health Care & Life Sciences » Pharmaceuticals | Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
26,868.20
30,691.50
104,793.10
116,426.30
97,773.40
Depreciation, Depletion & Amortization
23.20
25.50
139.60
196.90
213.90
Other Funds
40,087.10
-
-
-
-
Funds from Operations
26,453.60
26,348.80
92,867.30
100,750.10
83,355.70
Changes in Working Capital
3,862.30
3,541.60
9,412.60
9,492.80
2,863.90
Net Operating Cash Flow
22,591.30
22,807.20
102,280.00
91,257.20
80,491.80
Capital Expenditures
33.30
11.80
860.60
49.00
723.40
Purchase/Sale of Investments
1,500.00
66,722.50
360,918.80
92,311.40
91,994.30
Net Investing Cash Flow
1,466.70
66,734.30
361,779.40
92,262.40
92,717.70
Issuance/Reduction of Debt, Net
100.00
-
-
-
-
Net Financing Cash Flow
40,629.90
115,715.60
449,893.60
477.70
162,357.40
Net Change in Cash
19,505.40
26,174.10
14,165.70
1,482.90
10,852.10
Free Cash Flow
22,624.50
22,818.90
103,140.60
91,306.20
81,215.20
Deferred Taxes & Investment Tax Credit
-
-
-
-
1,058.40
Change in Capital Stock
442.80
115,715.60
449,893.60
477.70
162,357.40

About Intra-Cellular Therapies

View Profile
Address
430 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.intracellulartherapies.com
Updated 07/08/2019
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.